Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can you cut your arthritis meds without flaring up? new trial aims to find out

NCT ID NCT07160231

Disease control Sponsor: Sint Maartenskliniek Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at whether people with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who are doing well on a JAK inhibitor can safely reduce their dose. About 200 participants will either lower their dose or stay on the same dose, guided by disease activity. The goal is to see if the lower dose keeps the disease under control just as well after 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
JAK inhibitor dose reduction strategy
What this could lead to
If successful, this could show that many patients can safely lower their JAK inhibitor dose without losing disease control, reducing side effects and costs.
What could go wrong
This is a Phase 4 trial with 200 participants, so results may not apply to everyone. Lowering the dose might lead to disease flares in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients ≥ 16 years of age * Clinical diagnosis of RA, PsA or axSpA * Treated with a JAKi (monotherapy or combination with csDMARDwith a JAKi dose ≥ 50% of the authorised dose) * LDA or remission for at least 6 months according to accepted criteria for the specific disease and/or the judgement of the treating rheumatologist and patient. (RA: DAS28-CRP \< 2.9; PsA: PASDAS ≤3.2 and psoriasis mBSA involvement ≤3%; axSpA: ASDAS \<2.1.) Exclusion Criteria: * Comorbidity for which continued JAKi treatment is expected to be necessary (e.g. active Crohn's disease, ulcerative colitis) * Life expectancy ≤12 months * Pregnancy (JAKi are contra-indicated during pregnancy, therefore we do not expect patients using a JAKi while pregnant) * Patients who are enrolled in other trials that might mutually interfere * Not able to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Axial spondyloarthritis (axspa) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Axial Spondyloarthritis psoriatic arthritis rheumatoid arthritis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Axial spondyloarthritis (axspa) Psoriatic arthritis (PSA) Rheumatoid arthritis (RA

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Elisabeth-TweeSteden Ziekenhuis Tilburg

    NOT_YET_RECRUITING

    Tilburg, North Brabant, 5022 GC, Netherlands

  • Erasmus MC

    NOT_YET_RECRUITING

    Rotterdam, South Holland, 3015 GD, Netherlands

  • Isala Zwolle

    NOT_YET_RECRUITING

    Zwolle, Overijssel, 8025 AB, Netherlands

  • Maasstad ziekenhuis

    NOT_YET_RECRUITING

    Rotterdam, South Holland, 3079 DZ, Netherlands

  • Maastricht UMC+

    NOT_YET_RECRUITING

    Maastricht, Limburg, 6229 HX, Netherlands

  • Medisch Spectrum Twente

    NOT_YET_RECRUITING

    Enschede, Overijssel, 7512 KZ, Netherlands

  • Sint Maartenskliniek Nijmegen

    RECRUITING

    Nijmegen, Gelderland, 6574 NA, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.